相关实验视频

Updated: Jun 11, 2025

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

针对性测序的体质突变确定了晚期卵巢清细胞癌的风险分层

Shimeng Wan¹, Yang Gao¹, Sisi Wu²

¹Department of Gynecological Oncology, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China; Hubei Key Laboratory of Tumor Biological Behaviors, Wuhan, China; Hubei Cancer Clinical Study Center, Wuhan, China.

Gynecologic oncology

|September 29, 2024

概括

一个新的5基因小组,包括MUC16,ATM,NOTCH3,KMT2A和CTNNA1,有效预测晚期卵巢清细胞癌 (OCCC) 的预后和质反应,从而实现精确的药物策略.

科学领域:

在瘤学瘤学.
基因组学就是基因组学.
机器学习机器学习

背景情况:

卵巢清细胞癌 (OCCC) 是一种独特的上皮卵巢癌亚型.
先进的OCCC病例表现出患者的预后不佳.
需要风险分层来指导OCCC中的精密医学.

研究的目的:

为了识别高级OCCC的预后基因特征.
开发一个基因小组,用于OCCC的风险分层.
评估基因组的预测准确性与已确定的临床因素相比.

主要方法:

在44名晚期OCCC患者 (FIGOII-IV阶段) 上进行了下一代测序 (NGS).
采用机器学习算法 (XGBoost,RSF,Cox回归) 来识别预后基因.
构建并验证了5基因风险分层组,并使用ROC和决策曲线分析将其有效性与FIGO阶段和残留疾病进行了比较.

主要成果:

确定了MUC16,ATM,NOTCH3,KMT2A和CTNNA1作为关键预后突变基因.
与FIGO阶段和残留疾病相比,5基因小组在内部和外部队列中表现出对预后和白金反应的卓越预测能力.

结论:

在MUC16,ATM,NOTCH3,KMT2A和CTNNA1的突变与晚期OCCC的不良预后有关.
开发的5基因风险分层面板显示了对预后和反应的显著预测能力.
这种基因组具有作为OCCC精准医学新型生物标志物的潜力.

关键词:

基因面板基因面板卵巢清晰细胞癌的发生.风险分层是指风险的分层.有针对性的测序.

更多相关视频

Comparative Lesions Analysis Through a Targeted Sequencing Approach

Comparative Lesions Analysis Through a Targeted Sequencing Approach

Published on: November 5, 2019

Simple and Rapid Method to Obtain High-quality Tumor DNA from Clinical-pathological Specimens Using Touch Imprint Cytology

Simple and Rapid Method to Obtain High-quality Tumor DNA from Clinical-pathological Specimens Using Touch Imprint Cytology

Published on: March 21, 2018

相关概念视频

Cancers Originate from Somatic Mutations in a Single Cell

Cancers Originate from Somatic Mutations in a Single Cell

Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...